Gapping down
In reaction to disappointing earnings/guidance: NSR -24.6% (also authorizes share repurchase program for up to $200 mln of its Class A common shares beginning Jan 30, 2014 through Dec 31, 2014), INVN -8.1%, DEO -7.1%, HGG -6.7%, BVSN -6.2% (light volume), ELY -5.9%, WFT -5.9%, TSCO -5.8%, QTM -5.5% (light volume), CTXS -4.2%, (Templeton, will be returning from his previously announced leave of absence to resume his role as CEO; several analyst downgrades and one upgrade at Drexel Hamilton), SHW -4%(light volume), CDNS -3.8%, POT -3.4%, BTU -3.4%, MLNX -3%, TTEK -2.8%, (also awarded $60 mln U.S. Army Corps of Engineers Middle East District architect-engineer design services contract; awarded $60 mln environmental services contract for U.S. Coast Guard), KEX -2.3% (light volume), CELG -2.2%, SYMC -0.6%, LVS -0.5%, XOM -1.2%, BC -1.0%, SAN -0.5%.
Metals/mining stocks trading lower: AG -2.4%, EGO -2.4%, GDX -2.1%, SLV -1.9%, GOLD -1.8%, ABX -1.4%, HMY -1.4% (Harmony Gold downgraded to Neutral from Overweight at JPMorgan), AEM -1.3% GG -1.2% (Osisko commences legal proceeding to restrain misuse of confidential information by Goldcorp).
Select potash/ag related names showing early weakness following POT results: SYT -2.2%, IPI -2.2%, MOS -1.7%, SQM -1.3%.
Other news: KBIO -29% (reports top-line data for Phase 2 study of KB003 in severe asthma; while the study showed that KB003 was generally safe and well tolerated, it did not meet its primary clinical endpoint of improvement in FEV1 (a measurement of pulmonary function) compared to placebo in the overall study population), PLOW -5.9% (following TSCO results), IDIX -5.1% (following late weakness on patent news; Idenix Pharma confirms decision by the USPTO Trial and Appeal Board in the first patent interference; intend to challenge this decision), UL -2.6% (following DEO results), TSRO -2% (prices 3.2 mln shares of common stock at $31.50 per share ).
Analyst comments: SO -1.4% (downgraded to Neutral from Buy at Citigroup), EPB -0.7% (downgraded to Neutral from Buy at Goldman).
Metals/mining stocks trading lower: AG -2.4%, EGO -2.4%, GDX -2.1%, SLV -1.9%, GOLD -1.8%, ABX -1.4%, HMY -1.4% (Harmony Gold downgraded to Neutral from Overweight at JPMorgan), AEM -1.3% GG -1.2% (Osisko commences legal proceeding to restrain misuse of confidential information by Goldcorp).
Select potash/ag related names showing early weakness following POT results: SYT -2.2%, IPI -2.2%, MOS -1.7%, SQM -1.3%.
Other news: KBIO -29% (reports top-line data for Phase 2 study of KB003 in severe asthma; while the study showed that KB003 was generally safe and well tolerated, it did not meet its primary clinical endpoint of improvement in FEV1 (a measurement of pulmonary function) compared to placebo in the overall study population), PLOW -5.9% (following TSCO results), IDIX -5.1% (following late weakness on patent news; Idenix Pharma confirms decision by the USPTO Trial and Appeal Board in the first patent interference; intend to challenge this decision), UL -2.6% (following DEO results), TSRO -2% (prices 3.2 mln shares of common stock at $31.50 per share ).
Analyst comments: SO -1.4% (downgraded to Neutral from Buy at Citigroup), EPB -0.7% (downgraded to Neutral from Buy at Goldman).